Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jing Rong Jean Cui
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Beta
- 0.00
- Country
- US
Financials
BLSM has only 3 quarterly periods on file — the charts below show the full history available.
Net Income
$-23.76MEBITDA
$-24.67MFree Cash Flow
$-23.23MEPS (diluted)
$-8.75Shares Outstanding (diluted)
27.14M-6.7%Operating Expenses
$24.67MCash & Debt
$95.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-60.55M | $-2.08 |
| 2024 | $0.00 | $-30.70M | $-1.06 |
Valuation
BLSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+12.50%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·18d ago·Negative
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027
View source ↗ - Newsglobenewswire.com·28d ago·Negative
…esignation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.
View source ↗ - Newsglobenewswire.com·31d ago·Negative
… BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epid…
View source ↗ - Newsglobenewswire.com·45d ago·Negative
…e in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that updated data from the ongoing Phase 1/2 SOLARA trial describing anti-tumor activity of BH-30643 in patients with secondary epi…
View source ↗
Earnings
Typical surprise -844.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 18$-8.75 vs $-0.93miss
Estimates and results for BLSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLSM officers and directors.
No open-market trades in the recent filings. All 1 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BLSM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.